-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Beta Bionics, Raises Price Target to $23

Benzinga·09/15/2026 14:50:51
Listen to the news
Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $22 to $23.